Compagnie Lombard Odier SCmA’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
PCM
ACM
FCM
BFS
LGP
CS
LCM
NCM
Compagnie Lombard Odier SCmA's BMY.RT Position: Q4 2020 in Review
Compagnie Lombard Odier SCmA sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 600 shares — an estimated $2K sold.
Compagnie Lombard Odier SCmA first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $9K in Q4 2019. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.
- Compagnie Lombard Odier SCmA reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
- Compagnie Lombard Odier SCmA sold 600 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $2K.
- Compagnie Lombard Odier SCmA first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
- Compagnie Lombard Odier SCmA's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $9K in Q4 2019.
- 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2020, filed 9 Feb 2021.